Abstract
Shalman and colleagues reported a case of Guillain-Barré syndrome (GBS) whose clinical response to a second course of intravenous immunoglobulin (IVIG) treatments was associated with the albumin level in serum [1]. They concluded that serum albumin levels may be viewed a biomarker as part of the decision algorithm when a second course of IVIG treatment is considered [1]. This case report is interesting, and its finding is consistent with a former clinical trial suggesting that serum albumin could be a potential biomarker to monitor the treatment responses to IVIg among patients with GBS [2].
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
